Teva Pharmaceutical Industries

5-Star Stocks Poised to Pop: Teva Pharmaceutical

Fool.com (Free subscription) | 01/10/2008

Market-trouncing returns could be written in this 5-star.

Indevus: Making Big Gains with Approval for Its New Drug

Seeking Alpha (Free subscription) | 28/09/2008

Andrew Snyder submits: Indevus Pharmaceuticals (IDEV) was up by over 100% Friday. The big gains come thanks to positive news from the FDA and company executives signing a great business deal with Teva Pharmaceutical (TEVA). As the Wall Street mess is cleaned up, we will be seeing more winners just like this. The biotech industry is making headlines. Thanks to some positive news from the Food and Drug...

Israel Stocks: Market is higher; Alvarion gets a boost; economy seen slower

Market Watch (Free subscription) | 25/09/2008

Israeli stocks rise on Thursday, led by Israel Chemicals, Teva Pharmaceutical and Bank Leumi, with the real-estate stocks continuing to rebound.

Teva Pharmaceutical to enter Japan via joint venture

Market Watch (Free subscription) | 23/09/2008

HONG KONG (MarketWatch) -- Israel's Teva Pharmaceutical Industries Ltd. , the world's leading generic drug maker, will set up a development and sales joint venture with Kowa Co. as part of comprehensive effort to break into the Japanese market, according to a Japanese media report. The two sides are in the final stages of negotiations and expected to sign an agreement by the end of the month, the...

Israel Stocks: Israel stocks down for 12th day in 14; Teva set back by court

Market Watch (Free subscription) | 14/09/2008

Israeli stocks close lower for the 12th trading day in the past 14, with Teva Pharmaceutical and the banks leading the downside, offset by gains in Israel Chemicals, its parent, and cellular provider Cellcom.

Israel Stocks: Market lower; Israel Chemicals plans a buyback

Market Watch (Free subscription) | 04/09/2008

Israel stocks slipped on Thursday, with bounces in Israel Chemicals and Teva Pharmaceutical offset by a drop in Israel Corp.

Israel Stocks: Tel Aviv snaps five-session losing run; Alony Hetz climbs

Market Watch (Free subscription) | 02/09/2008

Israeli stocks snapped a five-day losing streak, led upward by the banks, Teva Pharmaceutical and the telecom stocks, with all but three of the blue chips moving higher.

Azilect data points to Parkinson's efficacy

Fiercebiotech (Free subscription) | 26/08/2008

Teva Pharmaceutical is touting the results of a late-stage study of Azilect, a treatment for Parkinson's disease. Researchers say the therapy hit all of its goals in the ADAGIO trial. Patients taking a once-daily oral dose of the drug reported a slowing of disease progression early on in the trial with a reduction in symptoms at a later point in the trial. The drug is already approved for treating...

• ADAGIO Trial Results Show Teva's AZILECT(R) 1 mg Tablets Slow Progression of Parkinson's Disease - Business Wire
• ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression of Parkinson's Disease - Red Orbit

Merger Watch: Barr Pharmaceuticals - Teva Pharmaceutical

Seeking Alpha (Free subscription) | 22/08/2008

The M & A Researcher submits: First, this August 14 Financial Times article will be referenced as it essentially echoes this publication's original assessment of the Barr Pharmaceuticals (BRL) - Teva Pharmaceutical (TEVA) transaction upon announcement last month. Of particular interest in this piece are the following passages from an third-part analytical report: An analyst report by Sanford C. Bernstein...

Cel-Sci inks deal with Teva; Pharmaxis touts Phase III data; BioCenter expands

Fiercebiotech (Free subscription) | 20/08/2008

> Cel-Sci has struck a development and commercialization deal with Teva Pharmaceutical for the cancer drug Multikine. Release > Pharmaxis announced that the Phase III clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attributed to the drug following 12 months of treatment. Release > San Jose BioCenter, a biotech...

Stada climbs on report Teva in talks to buy it

Market Watch (Free subscription) | 15/08/2008

LONDON (MarketWatch) -- Shares of Stada Arzneimittel rose 12%after the Israeli online financial site Globes reported that Teva Pharmaceutical is in talks to buy Germany's third-largest generics maker even before the Barr Pharmaceuticals deal closes. The report cited unnamed sources and said neither company commented. The site noted that Teva's CEO Shlomo Yanay previously said that the company has...

Israel Stocks: ICL surges again; Delek Group reiterated a buy

Market Watch (Free subscription) | 22/07/2008

Israeli stocks fell on Tuesday, snapping a three-session winning streak, with the banks and Teva Pharmaceutical leading the losers and Israel Chemicals rising for a second day after an analyst upgrade.

Teva Pharmaceutical goes bargain hunting, picks up Barr Pharmaceuticals for $7.46b :: israelplug - innovations. made in israel.

Israelated (Free subscription) | 22/07/2008

According to Haaretz, Teva has been going on a “little” shopping spree, buying companies as if they were cute pairs of shoes they just had to have. (And FYI, this Teva company has no connection to the Israeli hikers’ beloved Teva sandal co., incidentally made in China.) Recently, Teva purchased Barr Pharmaceuticals, “the fourth largest generic firm in the U.S., for $7.46 billion.” Teva had previously...

Israel Stocks: Market higher; Israel Chemicals and Teva upgraded

Market Watch (Free subscription) | 21/07/2008

Israel stocks rise strongly, helped by broker upgrades at Israel Chemicals and at Teva Pharmaceutical in the wake of its bid to acquire Barr Pharmaceuticals.

Teva Pharmaceutical upgraded to buy at Deutsche Bank

Market Watch (Free subscription) | 21/07/2008

LONDON (MarketWatch) -- Deutsche Bank upgraded Teva Pharmaceutical Industries to buy from hold, saying the group's plan to purchase Barr Pharmaceuticals Inc. for around $7.5 billion will enhance its growth prospects over the next four years. "Strategically, this transaction makes a lot of sense given little overlap in the two companies' businesses. First, Teva would benefit in the U.S. from an expanded...